Literature DB >> 26006250

Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

Nikolaos Tsamandouras1, Thierry Wendling, Amin Rostami-Hodjegan, Aleksandra Galetin, Leon Aarons.   

Abstract

The utilisation of physiologically-based pharmacokinetic models for the analysis of population data is an approach with progressively increasing impact. However, as we move from empirical to complex mechanistic model structures, incorporation of stochastic variability in model parameters can be challenging due to the physiological constraints that may arise. Here, we investigated the most common types of constraints faced in mechanistic pharmacokinetic modelling and explored techniques for handling them during a population data analysis. An efficient way to impose stochastic variability on the parameters of interest without neglecting the underlying physiological constraints is through the assumption that they follow a distribution with support and properties matching the underlying physiology. It was found that two distributions that arise through transformations of the normal, the logit-normal generalisation and the logistic-normal, are excellent for such an application as not only they can satisfy the physiological constraints but also offer high flexibility during characterisation of the parameters' distribution. The statistical properties and practical advantages/disadvantages of these distributions for such an application were clearly displayed in the context of different modelling examples. Finally, a simulation study clearly illustrated the practical gains of the utilisation of the described techniques, as omission of population variability in physiological systems parameters leads to a biased/misplaced stochastic model with mechanistically incorrect variance structure. The current methodological work aims to facilitate the use of mechanistic/physiologically-based models for the analysis of population pharmacokinetic clinical data.

Entities:  

Mesh:

Year:  2015        PMID: 26006250     DOI: 10.1007/s10928-015-9418-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  37 in total

Review 1.  Pharmacokinetic strategies in deciphering atypical drug absorption profiles.

Authors:  Honghui Zhou
Journal:  J Clin Pharmacol       Date:  2003-03       Impact factor: 3.126

Review 2.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption.

Authors:  Chantal Csajka; David Drover; Davide Verotta
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

4.  Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.

Authors:  Ivelina Gueorguieva; Leon Aarons; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-29       Impact factor: 2.745

5.  Semiparametric distributions with estimated shape parameters.

Authors:  Klas J F Petersson; Eva Hanze; Radojka M Savic; Mats O Karlsson
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

6.  Protein binding and hepatic clearance: discrimination between models of hepatic clearance with diazepam, a drug of high intrinsic clearance, in the isolated perfused rat liver preparation.

Authors:  M Rowland; D Leitch; G Fleming; B Smith
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

7.  PopGen: A virtual human population generator.

Authors:  Kevin McNally; Richard Cotton; Alex Hogg; George Loizou
Journal:  Toxicology       Date:  2013-07-19       Impact factor: 4.221

8.  Inter- and intrasubject variability of solid and liquid gastric emptying parameters. A scintigraphic study in healthy subjects and diabetic patients.

Authors:  S Lartigue; Y Bizais; S B Des Varannes; A Murat; B Pouliquen; J P Galmiche
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

9.  Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics.

Authors:  F Y Bois
Journal:  Environ Health Perspect       Date:  2000-05       Impact factor: 9.031

Review 10.  Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues.

Authors:  B Wulkersdorfer; T Wanek; M Bauer; M Zeitlinger; M Müller; O Langer
Journal:  Clin Pharmacol Ther       Date:  2014-03-28       Impact factor: 6.875

View more
  8 in total

1.  Accounting for inter-correlation between enzyme abundance: a simulation study to assess implications on global sensitivity analysis within physiologically-based pharmacokinetics.

Authors:  Nicola Melillo; Adam S Darwich; Paolo Magni; Amin Rostami-Hodjegan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-03-23       Impact factor: 2.745

2.  Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.

Authors:  Kosuke Doki; Adam S Darwich; Brahim Achour; Aleksi Tornio; Janne T Backman; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

3.  Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution.

Authors:  Estelle Yau; Andrés Olivares-Morales; Michael Gertz; Neil Parrott; Adam S Darwich; Leon Aarons; Kayode Ogungbenro
Journal:  AAPS J       Date:  2020-02-03       Impact factor: 4.009

4.  Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin.

Authors:  Andrés Olivares-Morales; Avijit Ghosh; Leon Aarons; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-09-08       Impact factor: 4.009

5.  Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System.

Authors:  N Tsamandouras; T Kostrzewski; C L Stokes; L G Griffith; D J Hughes; M Cirit
Journal:  J Pharmacol Exp Ther       Date:  2016-10-19       Impact factor: 4.030

6.  Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.

Authors:  Thierry Wendling; Nikolaos Tsamandouras; Swati Dumitras; Etienne Pigeolet; Kayode Ogungbenro; Leon Aarons
Journal:  AAPS J       Date:  2015-11-04       Impact factor: 4.009

7.  Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics.

Authors:  Thierry Wendling; Swati Dumitras; Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-01       Impact factor: 2.745

8.  A latent variable approach to account for correlated inputs in global sensitivity analysis.

Authors:  Nicola Melillo; Adam S Darwich
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-25       Impact factor: 2.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.